Skip to content
ReframedNewsLeft · Right · Centered
Quick ReadArchiveAboutSign in
Briefing stories›Business & Markets

AstraZeneca and Bristol Myers Squibb Held Talks on Combination Valued Near $400bn, Reports Say

Story date · Sunday, August 2, 2026Business & MarketsWell-covered

The facts

  • AstraZeneca and Bristol Myers Squibb held discussions in recent months about combining the two companies, according to a Financial Times report citing people familiar with the matter.
  • A combined company would have a market value of close to $400bn (about £300bn), which would make it the fourth-largest drugmaker in the world by market capitalisation.
  • AstraZeneca is the second most valuable listed company in the UK, with a market value of about £196bn (roughly $264bn), while Bristol Myers Squibb, headquartered in Princeton, New Jersey, is worth about $133bn.
  • AstraZeneca's London-listed shares fell by roughly 6.5% to 7% on Monday following the reports, making it one of the biggest fallers on the FTSE 100.
  • Investors and analysts questioned the logic of the combination, saying AstraZeneca had no obvious need for a transformative acquisition despite potential financial benefits.
  • A person familiar with the situation said a potential deal would carry regulatory risk over how US antitrust authorities under the Trump administration might assess it, with Trump focused on domestic investment and expanding US manufacturing.
  • Both companies have large oncology businesses, an overlap that analysts and investors expect to attract regulatory scrutiny; Bristol Myers Squibb is best known for its cancer treatments.
  • Sources said a deal could materialise soon but could also be delayed or fall apart, and no deal structure has been disclosed.
  • AstraZeneca declined to comment on the reports, and Bristol Myers Squibb did not immediately respond to requests for comment.

Context

Why did AstraZeneca's share price fall if it is the potential buyer?

AstraZeneca's London-listed shares dropped about 6.5% to 7% on Monday, the largest decline on the FTSE 100 CNBC,Terra,Yahoo! Finance. Investors and analysts said the UK's biggest drugmaker had no obvious need for a transformative acquisition despite potential financial benefits, and one report described the sell-off as a typical market reaction when a large-cap company is identified as the acquirer in a deal of this scale Terra,Investing.com.

What obstacles could stop the deal?

A person familiar with the situation told Reuters that a transaction would carry regulatory risk because of how US antitrust authorities under President Donald Trump might assess it, noting Trump's focus on domestic investment and expanding US manufacturing Yahoo! Finance,N-tv. Analysts also flagged the overlap between the two companies' oncology franchises as a likely focus of antitrust scrutiny Investing.com. Sources cautioned that the talks could be delayed or fall apart entirely, and no deal structure has been disclosed Yahoo! Finance,Investing.com.

How big would the combined company be, and where do the two firms operate?

The merged group would be valued at close to $400bn, placing it fourth among the world's pharmaceutical companies by market capitalisation Independent,ANSA.it,eldiario.es. AstraZeneca is headquartered in Cambridge, England, and led by chief executive Pascal Soriot Yahoo! Finance,Yahoo! Finance,Guardian. Bristol Myers Squibb is based in Princeton, New Jersey; its UK research team is based at Moreton on the Wirral, with a UK and Ireland commercial head office in Uxbridge Guardian,Yahoo! Finance.

Common ground, and where they split

Common ground
Neither framing sees a need for a deal this size: the overlap and scale are real, and the burden of justifying them sits with management, not skeptics.
Where Left and Right split
Who ends up controlling the cancer medicines patients depend on, or whose money executives are spending to buy global rank.

How left and right read it

Left says

Two of the world's largest cancer-drug makers discussing a combination worth close to $400bn raises a plain question about who ends up controlling the medicines patients depend on — and their overlapping oncology businesses are the sort of concentration antitrust review is meant to catch. Even investors saw no need for a deal this big. Any scrutiny should turn on competition, not on an administration's appetite for domestic investment and manufacturing.

“The FTSE 100 firm completed a new additional listing on the New York Stock Exchange in June as a result, in a blow to the London markets.” — The Independent↗

Right says

Shares in Britain's second most valuable listed company dropped some 6.5% to 7% on Monday, among the FTSE 100's worst, the moment word of a near-$400bn combination surfaced. Owners questioned the logic and saw no obvious need for a transformative deal. That is the price signal doing its job. Capital belongs to shareholders, not to executives chasing rank among the world's largest drugmakers — let management justify the scale before pursuing it.

“AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb” — The Telegraph↗

See this differently than someone you know would?

The receipts — 100 sources

Wire services (7)

ReutersLondon South EastAstraZeneca shares slide 7% after reports of Bristol Myers t...
ReutersYahoo! FinanceAstraZeneca held talks with Bristol Myers Squibb on $400 bil...
ReutersYahoo! FinanceAstraZeneca holds talks with Bristol Myers Squibb on $400 bi...
ReutersSun HeraldAstraZeneca holds talks with Bristol Myers Squibb on $400 bi...
ReutersInvesting.comAstraZeneca holds talks with Bristol Myers Squibb on $400 bi...
ReutersReutersAstraZeneca holds talks with Bristol Myers Squibb on $400 bi...
ReutersLondon South EastAstraZeneca holds talks with Bristol Myers Squibb on potenti...

Other coverage (93)

rsiAstraZeneca punta Bristol Myers Squibb: una fusione da 400 m...
CityAMAstrazeneca share price tumbles as investors doubt merger wi...
europa pressAstraZeneca baja más de un 7% entre rumores sobre una megafu...
The IndependentAstraZeneca share prices drop amid £300bn mega-merger talks ...
Süddeutsche ZeitungInsider: Mega-Fusion zwischen Astra Zeneca und Bristol Myers...
BFM Bourse"Les méga-fusions dans la pharmacie sont rares, et peu d'ent...
Le SoirDeux géants pharmaceutiques envisagent une fusion à 400 mill...
The Wall Street JournalStocks to Watch: Bristol Myers Squibb, Alibaba, Palantir
Il Sole 24 OREAstrazeneca giù a Londra, per Ft tratta una mega-fusione con...
RTP - Rádio Televisão PortuguesaFarmacêuticas AstraZeneca e BMS avaliam fusão em negócio de ...
Free Malaysia TodayAstraZeneca's shares slide 7% after reports of Bristol Myers...
QuiFinanzaAstraZeneca, maxi fusione da 400 miliardi: cosa cambia per B...
Jornal ExpressoAstraZeneca negoceia fusão de €348 mil milhões com Bristol M...
Economie MatinAstraZeneca : le pari à 400 milliards qui divise Wall Street
Yorkshire PostAstraZeneca in talks over £300bn mega-merger with US rival, ...
SudOuest.frPharmacie : AstraZeneca et Bristol Myers Squibb envisagent u...
wallstreet:onlineAstraZeneca & Bristol Myers: 400-Milliarden-Fusion - die Bör...
Le Figaro.frLes laboratoires AstraZeneca et BMS envisagent une fusion po...
Capital.frAstraZeneca discute avec Bristol Myers Squibb dans le cadre ...
NewsBytesAstraZeneca, BMS discuss $400B pharma mega-deal
The Border MailAstraZeneca shares drop on reports of $570b mega-merger
BoursoramaPharmacie: AstraZeneca et BMS envisagent une fusion à 400 mi...
TerraAções da AstraZeneca caem 7% após notícias sobre negociações...
BolsamaniaAstraZeneca cae con fuerza por las posibles negociaciones de...
El ConfidencialAstraZeneca se desploma un 6% en bolsa ante su posible fusió...
Wirtschafts WocheAstraZeneca-Aktie: Pharmaunternehmen prüft offenbar Fusion m...
eldiario.esLas farmacéuticas AstraZeneca y Bristol Myers Squibb negocia...
MorningstarAstraZeneca Shares Drop After Reports of Bristol Myers Squib...
AOL.comAstraZeneca and Bristol Myers Squibb in reported merger talk...
birminghampostAstraZeneca & Bristol Myers Squibb reportedly in £300m merge...
El EspañolAstraZeneca y BMS exploran una posible fusión para crear a u...
TeleborsaAstrazeneca peggior titolo del FTSE 100 dopo indiscrezioni s...
www.Bluewin.chAccording to media reports, AstraZeneca is exploring a mega-...
Investing.comWhy is AstraZeneca stock tumbling today? By Investing.com
Milano FinanzaAstraZeneca e Bristol Myers trattano la maxi fusione, può na...
YahooAstraZeneca holds talks with Bristol Myers Squibb on $400bn ...
Yahoo! FinanceAstraZeneca shares slide 7% on talks to buy Bristol Myers Sq...
Rai newsAstraZeneca-Squibb: in arrivo megafusione da 400 miliardi di...
London South EastAstraZeneca, Bristol Myers Squibb in talks over $400bn tie-u...
CNBCAstraZeneca shares drop 7% after report on $400 billion merg...
BOLSAMANIAAstraZeneca, Bristol Myers Squibb in talks over $400bn tie-u...
Yahoo! FinanceAstraZeneca in talks over £300bn mega-merger with US rival -...
Oggi TrevisoAstraZeneca tratta la fusione con Bristol Myers Squibb: a Lo...
The GuardianAstraZeneca holds talks with Bristol Myers Squibb on $400bn ...
YahooAstraZeneca holds talks with Bristol Myers Squibb on $400bn ...
AOL.comAstraZeneca holds talks with Bristol Myers Squibb over $400b...
Insider Media LtdAstraZeneca holds $400bn tie-up talks with Bristol Myers Squ...
finanzen.atAstraZeneca-Aktie: Konzern prüft wohl Mega-Fusion mit Bristo...
finanzen.chAstraZeneca-Aktie: Pharmariese prüfte wohl Übernahme von Bri...
CityAMAstrazeneca explores $400bn megadeal with US rival
wallstreet:onlineAstrazeneca prüft Mega-Fusion mit US-Konkurrenten Bristol My...
CashKreise: Astrazeneca prüft Mega-Fusion mit US-Konkurrenten Br...
finanzen.chKreise: Astrazeneca prüft Mega-Fusion mit US-Konkurrenten Br...
Finanz und WirtschaftAstraZeneca prüft Fusion mit Bristol Myers Squibb
finanzen.atKreise: Astrazeneca prüft Mega-Fusion mit US-Konkurrenten Br...
Affari ItalianiAstrazeneca tratta con un colosso farmaceutico Usa per una m...
DAGOSPIAla britannica astrazeneca tratta la maxi fusione con la riva...
Kent OnlineAstraZeneca in talks over £300bn mega-merger with US rival -...
London South EastPRESS: AstraZeneca and Bristol Myers-Squibb eye USD400 billi...
N-tvDer Börsen-Tag: 400-Milliarden-Fusion in der Pharmabranche?
RTTNewsAstraZeneca And Bristol Myers Reportedly In Talks On $400 Bl...
Wirtschafts WocheAstraZeneca: Pharmaunternehmen prüft offenbar Fusion mit Bri...
manager magazinAstraZeneca: Pharmakonzern prüft 400-Milliarden-Dollar-Fusio...
TeleborsaAstraZeneca, FT: tratta con Bristol Myers Squibb per fusione...
Cinco DíasAstraZeneca negocia con Bristol Myers Squibb una megafusión ...
ANSA.itFinancial Times: 'AstraZeneca tratta con Bristol Myers Squib...
El EconomistaAstraZeneca y Bristol Myers Squibb negocian mega acuerdo de ...
Business StandardAstraZeneca holds talks with Bristol Myers Squibb on $400 bi...
Frankfurter AllgemeineBusiness-Liveticker: AstraZeneca prüft laut Insider Fusion m...
Markets InsiderAstraZeneca in discussions to combine with Bristol Myers for...
Il Sole 24 OREBorsa Londra: -6% Astrazeneca, per Ft tratta mega-fusione co...
Il Sole 24 ORE*** AstraZeneca: in trattative con Bristol Myers Squibb per ...
The Business TimesAstraZeneca held talks with Bristol Myers Squibb on US$400 b...
Financial Times NewsFirstFT: AstraZeneca and Bristol Myers Squibb discuss $400bn...
New York PostAstraZeneca holds talks with Bristol Myers Squibb on $400B m...
Tech TimesAstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve...
FortuneAstraZeneca said to have explored Bristol Myers merger | For...
Yahoo! FinanceAstraZeneca and Bristol-Myers Squibb in talks over potential...
Investing.comAstraZeneca and Bristol-Myers Squibb in talks over potential...
Yahoo!AstraZeneca y Bristol Myers Squibb: el megacuerdo de U$S 400...
Revista SÁBADOBritânica AstraZeneca estuda fusão com a rival americana Bri...
LesEchos.frPharmacie : vers une potentielle fusion à 400 milliards de d...
Yahoo! FinanceAstraZeneca plots £300bn tie-up with US rival
The TelegraphAstraZeneca plots £300bn tie-up with US rival
The Straits TimesAstraZeneca holds talks with Bristol Myers Squibb on potenti...
Portal A TARDEAstraZeneca prepara fusão de US$ 400 bi com farmacêutica dos...
CNBCAstraZeneca in talks with Bristol Myers Squibb on $400 billi...
Valor EconômicoAstraZeneca explora possível fusão com a Bristol Myers Squib...
Salzburger NachrichtenAstraZeneca und Bristol MyersSquibb wollen Mega-Fusion
Jornal de NegóciosBritânica AstraZeneca estuda fusão com a rival americana Bri...
CashAstraZeneca erwägt offenbar Mega-Fusion mit US-Rivalen Brist...
CashAstraZeneca prüft 400-Milliarden-Dollar-Fusion mit Bristol M...
Financial Times NewsAstraZeneca holds talks with Bristol Myers Squibb on pharma ...

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

← Earlier in this briefing
Reuters Review Finds Chinese Military-Linked Researchers Used OpenAI, Anthropic ...
A Reuters review of more than 80 Chinese academic papers and patents found that researchers linked to China's military...
Technology & Society
Next in this briefing →
Japan and U.S. Confirm Joint Currency Intervention to Support the Yen
Japan's Finance Ministry said on Monday that it bought yen on Friday, July 31, in coordination with the U.S. Treasury,...
Business & Markets

Continue Reading

Related this week

Canada pledges up to C$560 million to Brazilian-led tropical forest fund

Canada pledged up to C$560 million (US$392.5 million) over four years to the Brazilian-led Tropical Forests Forever...

Science & Climate
From this briefing

Imprisoned Former Venezuelan President Maduro Voices Support for Political Talks Ahead of First In-Person Round

Nicolás Maduro, the deposed Venezuelan president held in a Brooklyn federal jail since a US military operation in...

International Affairs
Back to all stories

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

ReframedNews

A daily news briefing on the day’s top stories, built to show both sides.

Written by AI from news reporting. We review published briefings. Who writes this →

Navigate

Quick ReadArchiveSettings

Company

AboutHow it worksSkylark CreationsSign InTerms of ServicePrivacy Policy

© 2026 Reframed.News

Made by Skylark Creations